Palisade Bio, INC 10-Q quarterly reports

Palisade Bio, Inc. filed its Q1 2026 10-Q report, detailing a net loss of $9.6 million and significant increases in R&D and G&A expenses, while highlighting positive clinical trial results for its lead candidate, PALI-2108.

Palisade Bio reported positive Phase 1 clinical trial results for PALI-2108 in IBD, secured $138 million in a public offering, and addressed its going concern status, despite ongoing net losses and internal control weaknesses.

Palisade Bio announced a reduced net loss in Q2 2025, positive Phase 1 clinical trial results for PALI-2108, and a recent $3.9 million warrant exercise, but faces ongoing going concern doubts and Nasdaq compliance monitoring.

Palisade Bio announces its Q1 2025 financial results, showcasing a decrease in net loss and providing updates on the clinical development of its lead product candidate, PALI-2108.

Palisade Bio's Q3 2024 report highlights progress in their PALI-2108 clinical program, including the commencement of a Phase 1 trial, while also noting ongoing financial challenges.

Palisade Bio's second quarter 2024 report highlights ongoing development of PALI-2108, recent financings, and a focus on cost management.

Palisade Bio's first quarter 2024 results show increased R&D spending focused on PALI-2108, with a net loss of $3.5 million and recent financing activities providing runway into early 2025.